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Summary: Testing hospitalized patients with HIV in South Africa and Malawi for tuberculosis by the 
novel FujiLAM urine assay is likely to increase life expectancy and be cost-effective. These results can 






















Background: A novel urine lipoarabinomannan assay (FujiLAM) has higher sensitivity and higher cost 
than the first-generation AlereLAM assay. We evaluated the cost-effectiveness of FujiLAM for 
tuberculosis testing among hospitalized people with HIV irrespective of symptoms. 
 
Methods: We used a microsimulation model to project clinical and economic outcomes of three 
testing strategies: 1) sputum Xpert MTB/RIF (Xpert); 2) sputum Xpert plus urine AlereLAM 
(Xpert+AlereLAM); 3) sputum Xpert plus urine FujiLAM (Xpert+FujiLAM). The modelled cohort 
matched that of a two-country clinical trial. We applied diagnostic yields from a retrospective study 
(yields for Xpert/Xpert+AlereLAM/Xpert+FujiLAM among those with CD4<200/µL: 33%/62%/70%; 
among those with CD4≥200/µL: 33%/35%/47%). Costs of Xpert/AlereLAM/FujiLAM were USD15/3/6 
(South Africa) and USD25/3/6 (Malawi). Xpert+FujiLAM was considered cost-effective if its 
incremental cost-effectiveness ratio (USD/year-of-life saved) was <$940 (South Africa) and <$750 
(Malawi). We varied key parameters in sensitivity analysis and performed a budget impact analysis 
of implementing FujiLAM countrywide. 
 
Results: Compared with Xpert+AlereLAM, Xpert+FujiLAM increased life expectancy by 0.2 years for 
those tested in South Africa and Malawi. Xpert+FujiLAM was cost-effective in both countries. 
Xpert+FujiLAM for all patients remained cost-effective compared with sequential testing and CD4-
stratified testing strategies. FujiLAM use added 3.5% (South Africa) and 4.7% (Malawi) to five-year 






















Conclusions: FujiLAM with Xpert for tuberculosis testing in hospitalized people with HIV is likely to 
increase life expectancy and be cost-effective at the currently anticipated price in South Africa and 
Malawi. Additional studies should evaluate FujiLAM in clinical practice settings.  
 






















Tuberculosis (TB) is the leading cause of death of people with HIV (PWH) worldwide [1]. In sub-
Saharan Africa, TB accounts for approximately 40% of hospital deaths among PWH, and half of these 
are undiagnosed before death [2,3]. Sputum-based diagnostics, the current standard, suffer from 
the inability of some patients to produce sputum, the low sensitivity of smear, and the cost of 
molecular diagnostics. Moreover, extrapulmonary TB may be missed by sputum-based testing. 
 
Urine-based assays for lipoarabinomannan (LAM) are a promising TB testing approach. Testing 
hospitalized PWH using a first-generation LAM lateral flow assay (Determine TB-LAM®; Alere; 
hereupon called AlereLAM) increases TB diagnostic yield and, in some subgroups, reduces mortality 
[4,5]. However, AlereLAM’s limited sensitivity hinders more widespread clinical benefit. 
 
The next-generation Fujifilm SILVAMP TB-LAM assay (FujiLAM) offers higher sensitivity than 
AlereLAM for TB detection [6–8]. A study using biobanked urine from hospitalized PWH in South 
Africa found FujiLAM’s sensitivity against a microbiologic reference standard to be 70%, compared 
with 42% for AlereLAM [6]. Specificity for both assays was over 90%. Although both can provide a 
result in under one hour without additional instrumentation, FujiLAM involves additional steps, time, 
and cost compared with AlereLAM [6].  
 
Weighing additional TB detections and potential prevented deaths against additional costs is critical 
in deciding whether to implement FujiLAM in resource-limited settings. We therefore performed a 
cost-effectiveness analysis of urine FujiLAM added to sputum Xpert for TB testing among 






















We used the Cost-Effectiveness of Preventing AIDS Complications (CEPAC)-International model, a 
validated microsimulation of HIV- and TB-related disease and treatment [9–11]. The population of 
interest was adults with HIV, regardless of CD4 count or symptoms, hospitalized in medical units. We 
compared three TB testing strategies: 1) sputum Xpert alone (Xpert); 2) sputum Xpert and urine 
AlereLAM (Xpert+AlereLAM); 3) sputum Xpert and urine FujiLAM (Xpert+FujiLAM). To attain stable 
per-person results, we modelled cohorts of one million hospitalized PWH separately in South Africa 
and Malawi. We based our modelled population on participants in the Rapid Urine-based Screening 
for Tuberculosis to Reduce AIDS-related Mortality in Hospitalized Patient  in Africa (STAMP) trial in 
South Africa and Malawi, in which hospitalized PWH, irrespective of CD4 count or symptoms, were 
tested for TB by either sputum Xpert or sputum Xpert plus urine Xpert plus urine AlereLAM [5,12]. 
While the STAMP trial represented our target population, it did not include FujiLAM. Therefore, we 
based performance characteristics of all diagnostic assays on a study that used biobanked specimens 
from hospitalized PWH in South Africa [6]. 
 
Model outcomes included mortality, life expectancy, and TB- and HIV-related costs from the health 
system perspective. The primary outcome was the incremental cost-effectiveness ratio (ICER) – the 
difference in lifetime healthcare costs (2017 US dollars [USD]) divided by the difference in life 
expectancy – between testing strategies. A strategy was strongly dominated if it resulted in lower 
life expectancy than a less costly strategy. A strategy was weakly dominated if it resulted in a higher 
ICER than a strategy that provided higher life expectancy [13]. Because second-line antiretroviral 
therapy (ART) is relatively expensive but implemented and recommended in national HIV care 




















cost-effective, i.e., offering good value (Supplement) [14–16]. These thresholds were USD940/year-
of-life saved (YLS) in South Africa and USD750/YLS in Malawi [9]. 
 
Model Overview 
In this analysis, simulated PWH enter the model upon TB testing and are tracked monthly until 
death. Initially, the model draws randomly from user-defined characteristics in each country, such as 
distributions of CD4 count and TB status [10]. The model tracks clinical outcomes and costs as each 
individual transitions through various “states” of TB and HIV disease and treatment. Details about 
the model, validation, and treatment parameters are in the Supplementary Text, Supplementary 
Figure 1, Supplementary Table 1, and at massgeneral.org/medicine/mpec/research/cpac-model.  
 
Tuberculosis Diagnostics 
In the model, TB can be diagnosed from a positive test result. After diagnosis, individuals start 
treatment for drug-susceptible or multidrug-resistant TB (Supplement). In case of only negative 




We characterized the simulated population using STAMP trial data [5] (Table 1). Diagnostic data 
came from a cohort of hospitalized PWH, all of whom were tested for TB regardless of CD4 count or 
symptoms [6,17]. We used CD4-stratified (<200/μL or ≥200/μL) diagnostic performance data that 





















For performance characteristics of each testing strategy (Xpert, Xpert+AlereLAM, and 
Xpert+FujiLAM) in the model, we applied diagnostic yields, calculated as: the number of subjects 
who had a correct positive TB result by at least one test in the strategy, divided by the number of 
subjects diagnosed with TB by the composite reference standard, all from Broger et al. (Supplement) 
[6]. The diagnostic yield accounted for the number of subjects able to provide a specimen and the 
incremental diagnostic yield of the LAM tests over sputum Xpert (i.e., the additional cases detected 
by LAM that were not diagnosed by sputum Xpert, Supplement). We assumed 50% of individuals 
would provide a sputum specimen (Supplement). The diagnostic yields applied in our base case 
analysis were, for CD4/µL <200/≥200: Xpert, 33%/33%; Xpert+AlereLAM, 62%/35%; Xpert+FujiLAM, 
70%/47% (Table 1 and Supplement). We applied specificity of Xpert from a meta-analysis and 
specificity of AlereLAM and FujiLAM from Broger et al. [6,18].  
 
Costs 
In South Africa/Malawi, sputum Xpert costs were USD15/25 and urine AlereLAM costs were USD3/3 
[9,19–21]. Though the price of urine FujiLAM has not yet been established, we used in the base case 
a best estimate of the anticipated cost, USD6, which is also in line with the World Health 
Organization’s (WHO) target product profile [22]. We varied this cost from USD3 to USD20 in 






















Deterministic Sensitivity Analysis 
We performed one-way and multi-way deterministic sensitivity analysis by varying key parameters 
across ranges (Table 1). When varying FujiLAM sensitivity, we accounted for its impact on the 
diagnostic yield of Xpert+FujiLAM (Supplement).  
 
Probabilistic Sensitivity Analysis 
In a probabilistic sensitivity analysis, we simultaneously varied several parameters across beta 
distributions to understand how results would vary in other settings or scenarios (Supplement). 
These parameters were TB prevalence, sputum provision, empiric TB treatment, loss to follow-up 
from TB care, and death from untreated TB. We used the results to generate a cost-effectiveness 
acceptability curve. 
 
Alternative Testing Strategies 
We evaluated alternative TB testing strategies, including: solo strategies (Xpert, AlereLAM, or 
FujiLAM alone); sequential strategies (whereby a urine LAM test is done and, if positive, is followed 
by sputum Xpert for rifampicin-resistance testing); and CD4-stratified strategies (sputum Xpert plus 
urine LAM for those with CD4<200/μL; sputum Xpert alone for those with CD4≥200/μL). We 
compared the outcomes of these strategies to those of the three strategies of the base case, 
generating a cost-effectiveness frontier; strategies that lie on the frontier are economically efficient. 
We also evaluated a scenario in which Xpert Ultra was substituted for Xpert in each of the three base 
case strategies, offering higher sensitivity and lower specificity at similar cost to Xpert (Table 1 and 





















Budget Impact Analysis 
We conducted a budget impact analysis of performing Xpert+FujiLAM instead of Xpert countrywide 
among all hospitalized PWH over one year and five years, assuming 500,000 and 70,000 annual 
hospitalizations among PWH in South Africa and Malawi (Supplement) [9]. We considered FujiLAM 
per-test cost of either USD6 or USD20. 
RESULTS 
Base Case 
LAM strategies increased the number of positive TB results (Supplementary Table 2). In the base 
case analysis in South Africa and Malawi, Xpert+AlereLAM and Xpert+FujiLAM both reduced two-year 
mortality and increased life expectancy compared with Xpert (Table 2). Undiscounted life expectancy 
with Xpert/Xpert+AlereLAM/Xpert+FujiLAM was 13.2/13.7/13.9 years in South Africa and 
12.7/13.1/13.3 years in Malawi. Regarding cost-effectiveness, Xpert+AlereLAM was weakly 
dominated by the more effective Xpert+FujiLAM. In both countries, Xpert+FujiLAM was cost-
effective compared with Xpert, with ICER USD830/YLS in South Africa and USD440/YLS in Malawi 
(Table 2). 
 
Sensitivity and Uncertainty Analysis 
When varying key parameters in one-way sensitivity analysis, Xpert+AlereLAM was weakly 
dominated by Xpert+FujiLAM in most analyses in South Africa and Malawi (Supplementary Table 3). 
Xpert+FujiLAM remained cost-effective compared with Xpert in all these analyses except in South 
Africa when Xpert+FujiLAM yield was decreased by 20 percentage points (i.e., <50%/<27% for 





















In multi-way deterministic sensitivity analyses in which we varied TB prevalence, sputum provision, 
and empiric TB treatment probability, Xpert+FujiLAM was cost-effective compared with Xpert in 
South Africa except when both TB prevalence was relatively low (15%) and sputum provision 
probability was high (90%); Xpert+FujiLAM was cost-effective compared with Xpert in Malawi in all 
scenarios (Supplementary Figure 2). In a two-way sensitivity analysis where FujiLAM sensitivity and 
FujiLAM cost were varied, Xpert+FujiLAM remained cost-effective compared with Xpert in South 
Africa and Malawi except when FujiLAM had both relatively low sensitivity (≤42%) and higher cost 
(≥USD10/test) (Figure 1).  
 
In the probabilistic sensitivity analysis, there was a >95% probability that Xpert+FujiLAM offered the 
highest net monetary benefit when willingness-to-pay was >USD930/YLS in South Africa and 
>USD460/YLS in Malawi (Supplementary Figure 3).  
 
Alternative Testing Strategies 
Most solo, sequential, and CD4-stratified testing strategies were dominated by Xpert+FujiLAM 
(Supplementary Table 4). In South Africa, only AlereLAM alone, Xpert alone, and Xpert+FujiLAM were 
on the cost-effectiveness efficiency frontier (strategies below the frontier are dominated, Figure 2A). 
In Malawi, only AlereLAM alone, FujiLAM alone, and Xpert+FujiLAM were on the efficiency frontier 
(Figure 2B). Strategies that added LAM testing to Xpert provided notable gains in life expectancy at 
modest additional cost compared with Xpert alone, the more established strategy. Xpert+FujiLAM 
provided the most life-years in both countries. Strategies that included Xpert Ultra instead of Xpert 
reduced 2-year mortality modestly (<0.8%); cost-effectiveness results were similar to those of the 





















Budget Impact Analysis 
Over five years, testing all hospitalized PWH for TB with Xpert+FujiLAM instead of Xpert saved 
approximately 172,200 and 26,700 years of life in South Africa and Malawi. When FujiLAM per-test 
cost was USD6, Xpert+FujiLAM increased cumulative healthcare expenditures among tested 
individuals by approximately USD336million (3.5%) in South Africa and USD17 million (4.7%) in 
Malawi over five years, compared with Xpert (Figure 3). The largest contributors to the increase 
were non-TB, non-ART HIV care costs (70%/40% of increase in South Africa/Malawi). When excluding 
HIV care costs, Xpert+FujiLAM compared with Xpert increased five-year TB healthcare expenditures 
among tested individuals by approximately USD56 million (46%) in South Africa and USD7 million 
(40%) in Malawi. FujiLAM itself, at USD6 per test, contributed USD15 million (South Africa) and USD2 
million (Malawi) to these additional costs. When FujiLAM per-test cost was USD20, the increases in 
cumulative healthcare expenditures for both TB and HIV care were USD370 million (3.9%) in South 
Africa and USD22 million (6.1%) in Malawi. One-year budget impact results are in the Supplementary 
Text and Supplementary Figure 4. 
 
DISCUSSION 
In our model-based analysis, we found that testing hospitalized PWH for TB with sputum Xpert and 
urine FujiLAM together decreased mortality, increased life expectancy by 0.6-0.7 years, and was 
cost-effective compared with sputum Xpert testing alone in South Africa and Malawi. A testing 
strategy of Xpert plus FujiLAM outperformed and economically dominated an Xpert plus AlereLAM 
strategy. The results remained robust in sensitivity analysis in which key parameters were varied to 
reflect other possible settings and scenarios. A novel aspect of this analysis was our comparison of 
clinically-relevant parallel, solo, sequential, and CD4-stratified testing strategies – Xpert plus FujiLAM 





















In 2019, WHO expanded its recommendations for AlereLAM use for TB diagnosis – for inpatient 
PWH, WHO strongly recommends AlereLAM for those with signs and symptoms of TB, those with 
advanced HIV disease or who are seriously ill, and those with CD4 count <200/µL irrespective of 
signs and symptoms [24]. With its improved sensitivity, FujiLAM might be considered for broader use 
[6–8]. However, prospective studies to demonstrate feasibility, clinical outcomes, and cost in clinical 
practice settings will be important, as FujiLAM compared with AlereLAM requires additional steps 
(silver amplification) and time (50-60 minutes versus 25 minutes, including incubation) [6]. While we 
attempted to capture these operational factors by increasing the cost of FujiLAM, they are 
challenging to account for in cost-effectiveness analysis. Operational variability could influence 
FujiLAM accuracy and uptake but is unlikely to prolong time to treatment initiation after a positive 
result. 
 
The per-test price of FujiLAM has not been finalized, and there are no published microcosting 
estimates of FujiLAM in practice. A preliminary cost has been estimated at USD6 per test, in line with 
WHO’s target for a new TB diagnostic [22]. Our sensitivity analysis showed that, even at a higher per-
test cost, a testing strategy combining FujiLAM with sputum Xpert would be cost-effective compared 
with Xpert alone. Increasing the FujiLAM cost has little influence on the ICER – indeed, most 
incremental costs of FujiLAM strategies reflect years of HIV care for individuals who otherwise would 
die of undiagnosed TB.  
 
However, FujiLAM cost has a greater influence in the budget impact analysis, which accounts for the 
total number of people who would be tested. Though we did not fully account for the operational 




















increasing TB treatment capacity, our budget impact analysis of FujiLAM at a cost of USD20 per test 
indirectly reflects some of these factors by incorporating operational costs into the test cost. We 
show that adding FujiLAM would contribute a relatively small amount to the total healthcare costs 
for this patient population, and that much of the increase in costs is due to downstream positive 
effects of longer survival and not due to the test itself. Nonetheless, when considered in the isolated 
context of a TB control program, adding FujiLAM would consume a greater proportion of the 
program’s budget. Overall, FujiLAM offers clinical benefit and good value based on the ICER, but 
affordability must be considered in the context of budget and other resource constraints and the full 
costs of implementation. 
 
There is no consensus on appropriate cost-effectiveness thresholds in a given country [16]. As in a 
prior study, we used as our cost-effectiveness threshold the ICER of second-line ART, which is 
recommended for care by national guidelines in both South Africa and Malawi [9,14,15]. Alternative 
thresholds could affect interpretations of cost-effectiveness but would not change the model-
generated ICER results. 
 
Urine LAM assays are more sensitive in those with low CD4 compared with high CD4 counts [6]. 
Nonetheless, our analysis of CD4-stratified testing strategies showed that adding FujiLAM testing for 
all patients, rather than only for those with CD4<200/µL, would provide greater clinical benefit and 
be cost-effective. As CD4 testing for the diagnostic algorithm would add time delay, cost, and 
complexity (and it is being phased out in many settings), performing FujiLAM for all hospitalized 





















We previously conducted a cost-effectiveness analysis of the STAMP trial, finding that adding 
AlereLAM to Xpert was cost-effective compared with Xpert alone [9]. In the present study, 
Xpert+AlereLAM remained cost-effective compared with Xpert, but Xpert+FujiLAM was cost-effective 
compared with Xpert and Xpert+AlereLAM and yielded higher life expectancy than those strategies. 
Compared with the prior study’s results, we project fewer life-years in South Africa and a smaller 
difference in life-years between testing strategies in Malawi. These discrepancies are due to 
differences in diagnostic yields and other model parameters between the two studies. In our 
previous study, we applied parameters directly from the STAMP trial in which there were differences 
between South Africa and Malawi, including a much higher probability of sputum provision (75% 
versus 39%), higher probability of empiric treatment (10% versus 4%), and lower incremental 
diagnostic yield of AlereLAM (approximately 19% versus 52%) in South Africa compared with Malawi 
[5]. We assumed here that sputum provision probability, empiric treatment probability, and 
diagnostic yield would be similar in the two countries. Despite modest changes in these 
assumptions, both studies showed that adding LAM to Xpert would be cost-effective, and our 
sensitivity analyses in this study (which included the base case values from the STAMP cost-
effectiveness analysis) provide insight into results when parameters differ by country. Additional 
testing of urine by Xpert, as in the STAMP trial, could be considered. However, urine Xpert had only 
limited additional diagnostic yield above urine AlereLAM and sputum Xpert in STAMP, and it had 
disadvantages of requiring centrifugation and costing more than AlereLAM [5,9]. Xpert Ultra may 
offer greater yield.  
 
Like all model-based analyses, our study has limitations. We applied diagnostic yields from a 
retrospective study (with the attendant potential biases) that included all assays of interest, except 
for applying a base case sputum provision probability of 50% [5,6,17,25,26]. We chose this 




















AlereLAM and FujiLAM above sputum Xpert alone [6]. Our analysis accounted for false-positive test 
results in terms of costs of unnecessary TB treatment and of managing treatment toxicities but did 
not account for potential mortality from misdiagnosis and unnecessary treatment, which could 
temper the enthusiasm for more widespread implementation (though, because of an imperfect 
reference standard, some “false-positives” may be true-positives). Lacking data, we did not account 
for TB transmission, thus potentially underestimating population-level benefits of LAM testing in 
detecting TB, prompting treatment, and decreasing transmission. Finally, we adopted a health 
system perspective for costs and did not include patient costs, non-health system costs, or economic 
gains from improved survival. 
 
In conclusion, our model-based analysis found that adding urine FujiLAM to sputum Xpert for TB 
testing among unselected hospitalized PWH in South Africa and Malawi would increase life 
expectancy and be cost-effective. Though additional feasibility studies of FujiLAM are needed in 
clinical practice settings, the rapidity of the test procedure and its improved sensitivity over an 
earlier-generation LAM assay suggest that it would reduce deaths among hospitalized PWH in TB-
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Table 1. Model input parameters. 
Cohort characteristics South Africa Malawi Deterministic sensitivity analysis range References 
Age, years, median [IQR] 37 [30-46] 38 [32-47]  [5] 
Men/women, % 50/50 37/63  [5] 
CD4 count at admission, cells/µL, median [IQR] 236 [70-445] 219 [86-431]  [5] 
TB prevalence, %a 29 24 15-45b [5,9,27,28] 
MDR-TB prevalence among those with TB, % 3 1 1-7 (South Africa); 0.5-5 (Malawi) [5,29] 
Patients able to provide sputum, % 50 50 30-90b Assumption / 
[5,6,25] 
Probability of empiric treatment, Xpert, %c 11 11 0-20b [5,30] 
Probability of empiric treatment, 
Xpert+AlereLAM  
   and Xpert+FujiLAM, % 
10 10 0-20b [5,6] 
Loss to follow-up from TB care after hospital  
   discharge, %/month 
3.6 3.6 50%-200% of base case valueb [31,32] 
Mortality      
Death from untreated TB, monthly probability 0.086 0.086 25%-200% of base case valueb [33,34] 
Death from AIDS (besides TB), CD4-dependent,  
   monthly probability 
6.2x10-5-0.2 6.2x10-5-0.2  [35,36] 
Cost of treatmentd      
DS-TB treatment cost, monthly (6-month 
duration),  
   USD 
$7 $7  [37] 
MDR-TB treatment cost, monthly (24-month  
   duration), USD 
$231 $231  [37] 
First-line ART costs (TDF/3TC/EFV), monthly, USD $11 $11 50-75% of base case value  [38] 
Cost of TB diagnostic assay, per-test (USD)     
Sputum Xperte $15 $25  [19,20] 
Urine AlereLAM $3 $3  [21] 




















Table 1, continued. 
 
Performance characteristics of diagnostic assays and strategies 
   Diagnostic assayf Sensitivity Specificity Deterministic sensitivity analysis range References 
   Sputum Xpert, CD4<200/µL / ≥200/µL 65% / 65% 98% / 98%  [6], 
Assumption 
   Urine AlereLAM CD4<200/µL / ≥200/µL 48% / 2% 97% / 99%  [6], 
Assumption 




   Xpert Ultra, CD4<200/µL / ≥200/µL 77% / 77% 96% / 96%  [23] 
   Diagnostic strategyf Diagnostic yield   






   Xpert+AlereLAM, CD4<200/µL / ≥200/µL -20% to +20% of base case value [6], 
Assumption 
   Xpert+FujiLAM, CD4<200/µL / ≥200/µL -20% to +20% of base case value [6], 
Assumption 
 
Abbreviations: IQR, interquartile range; TB, tuberculosis; MDR, multidrug-resistant; DS, drug-susceptible; USD, United States dollars (2017); TDF, 
tenofovir; 3TC, lamivudine; EFV, efavirenz; LAM, lipoarabinomannan. 
 
aTB prevalence is the true prevalence among the simulated group of hospitalized patients with HIV. 
bThese parameters were also examined in probabilistic sensitivity analysis using beta distributions (Supplement). 



















dWe assumed that costs of TB drugs and ART drugs were equal across countries because they are imported across countries. Costs shown here 
are for drugs only. 
eXpert cost in a Malawi-specific costing study was higher than the cost reported in South African studies and by the South Africa National Health 
Laboratory Service [19]. This is due to factors such as different costs of maintenance and repair and different economies of scale. 
fThe indicated sensitivity of each assay is the sensitivity among those who provided a specimen and is independent of other test results. Italics 
reflect a diagnostic strategy rather than a single test. The diagnostic strategy yields applied in the model accounted for non-provision of sputum 
specimens and for concordance between test results – e.g., adding FujiLAM would increase diagnostic yield only if FujiLAM detected additional 
























Table 2. Base case model clinical, cost, and cost-effectiveness results. 
South Africa 
Testing strategy Mortality at  
2 years, % 
Life-years, discounteda 
(undiscounted) 
Cost, USD,  
Discounteda,b 
ICER, USD/YLSc 
Xpert 35.8 8.9 (13.2) 8,230 - 
Xpert+AlereLAM 33.3 9.2 (13.7) 8,500 dominatedd 
Xpert+FujiLAM 32.1 9.4 (13.9) 8,640 830 
Malawi 
Testing strategy Mortality at  
2 years, % 
Life-years, discounteda 
(undiscounted) 
Cost, USD,  
Discounteda,b 
ICER, USD/YLSc 
Xpert 38.9 8.5 (12.7) 3,540 - 
Xpert+AlereLAM 37.2 8.8 (13.1) 3,640 dominatedd 
Xpert+FujiLAM 36.2 8.9 (13.3) 3,710 440 
Abbreviations: USD, 2017 US dollars; ICER, incremental cost-effectiveness ratio; YLS, year-of-life saved. 
aDiscounted 3% per year [39]. 



















cThe ICER is the difference between two strategies in discounted costs divided by the difference in discounted life-years. The displayed life-years 
and costs are rounded, but the ICER was calculated using non-rounded life-years and costs. We considered a strategy cost-effective if its ICER 
was less than USD940/YLS in South Africa and less than USD750/YLS in Malawi (the ICERs of second-line antiretroviral therapy in these 
countries). 
 
dThis indicates “weak dominance” [40]. The ICER of Xpert+AlereLAM versus Xpert was higher (less attractive) than the ICER of Xpert+FujiLAM 























Figure 1. Two-way sensitivity analysis of FujiLAM sensitivity and cost. 
Abbreviation: USD, 2017 US dollars. 
 
We varied FujiLAM sensitivity and FujiLAM per-test cost across ranges and compared the cost-
effectiveness of Xpert, Xpert+AlereLAM, and Xpert+FujiLAM. The displayed sensitivities are weighted 
averages of the sensitivities among those with CD4 count <200/µL and ≥200/µL. The numbers in 
parentheses show the difference in sensitivity between FujiLAM and AlereLAM. In the green areas, 
Xpert+FujiLAM is cost-effective compared with both Xpert and Xpert+AlereLAM; it weakly dominates 
Xpert+AlereLAM, meaning that it is more effective and has a lower cost-effectiveness ratio than 
Xpert+AlereLAM. In the red hatched areas, Xpert+FujiLAM is not cost-effective compared with Xpert, but 
Xpert+AlereLAM is cost-effective compared with Xpert. 
 
*In the base case in both countries, FujiLAM is 15% more sensitive than AlereLAM and costs USD3 more 
per test. 
Figure 2. Cost-effectiveness frontier of alternative tuberculosis testing strategies in hospitalized 
people with HIV. 
We projected the life-years and lifetime costs associated with solo (green), parallel (orange), sequential 
(blue), and CD4-stratified (purple) tuberculosis testing strategies in South Africa (A) and Malawi (B). A 




















circles represent strategies that include FujiLAM. The testing strategies labelled on the cost-
effectiveness frontier line are those that were not dominated. Other strategies, represented by symbols 
below the line, were dominated, reflecting an inefficient use of resources. 
 
 
Figure 3. Budget impact analysis at five-year horizon: implementing FujiLAM testing countrywide in 
South Africa and Malawi among hospitalized patients with HIV. 
Abbreviations: USD, 2017 US dollars; ART, antiretroviral therapy. 
 
The vertical axis range is different between Panel A and Panel B. Budgetary projections are for the 
estimated 500,000 people with HIV who would be hospitalized each year in South Africa and 70,000 
people with HIV who would be hospitalized each year in Malawi, all of whom would undergo 
tuberculosis testing. Within each panel, the left bar represents five-year cumulative healthcare costs 
among these people if Xpert was the tuberculosis testing strategy. The middle bar reflects the 
Xpert+FujiLAM testing strategy, with FujiLAM costing USD6 per test. The right bar reflects the 
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